Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 17, 2018
Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
-
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...